Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment

Epilepsia

Volumn 39, Issue 1, 1998, Pages 27-32

  Guerrini, Renzo ^a   Belmonte, Anna ^a   Canapicchi, Raffaello ^a   Casalini, Claudia ^a   Perucca, Emilio ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Brain pseudoatrophy; Mental deterioration; MRI; Valproate

Indexed keywords

LAMOTRIGINE; PHENOBARBITAL; VALPROIC ACID;

ARTICLE; BRAIN ATROPHY; CASE REPORT; COGNITIVE DEFECT; DRUG BLOOD LEVEL; ELECTROENCEPHALOGRAM; EPILEPSY; FEMALE; HUMAN; HYPERAMMONEMIA; INTELLIGENCE QUOTIENT; MENTAL DETERIORATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCHOOL CHILD; SLEEP; WAKEFULNESS;

ATROPHY; BRAIN; BRAIN DISEASES; CHILD; COGNITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; ELECTROENCEPHALOGRAPHY; EPILEPSY; FEMALE; HUMANS; INTELLIGENCE TESTS; MAGNETIC RESONANCE IMAGING; MENTAL RETARDATION; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; VALPROIC ACID; WECHSLER SCALES;

EID: 0031931040     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1998.tb01270.x     Document Type: Article

References (14)

1. Davis R, Peters DH, McTavish D. Valproic Acid: A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332-72.
2. Marescaux C, Warter JM, Micheletti G, Rumbach L, Coquillat G, Kurtz D. Stuporous episodes during treatment with sodium valproate: Report of seven cases. Epilepsia 1982;23:297-305.
3. Zaccara G, Paganini M, Campostrini R, Arnetoli G, Zappoli R, Moroni F. Hyperammonemia and valproate-induced alterations of the state of consciousness: A report of 8 cases. Eur Neurol 1984; 23:104-12.
4. Sasso E, Delsoldato D, Negotti A, Mancia D. Reversible valproate-induced extrapyramidal disorders. Epilepsia 1994;35:391-3.
5. Armon C, Shin C, Miller P, et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996; 47:626-35.
6. Zaret BS, Cohen RA. Reversible valproic acid-induced dementia: a case report. Epilepsia 1986;27:234-40.
7. McLachlan RS. Pseudoatrophy of the brain with valproic acid monotherapy. Can J Neurol Sci 1987;14:294-6.
8. Dehling E, Wolf P. Reversible dementia after valproate therapy [Abstract]. Epilepsia 1990;2:227.
9. Papazian O, Canizales E, Alfonso I, Archila R, Duchowny M, Aicardi J. Reversible dementia and apparent brain atrophy during valproate therapy. Ann Neurol 1995;38:687-91.
10. Schondienst M. Cerebral and cerebellar atrophy caused by valproate? Four case reports [Abstract]. Epilepsia 1990;2:227.
11. Lagenstein I, Willig RP, Kühne D. Reversible cerebral atrophy caused by corticotropin. Lancet 1979;1:1246-7.
12. Tassinari CA, Bureau M, Dravet C, Dalla Bernardina B, Roger J. Epilepsy with continuous spikes and waves during slow sleep-otherwise described as ESES (epilepsy with electrical status epilepticus during slow sleep). In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, eds. Epileptic syndromes in infancy, childhood and adolescence. London: John Libbey & Company Ltd, 1992:245-56.
13. Sackellares JC, Lee SI, Dreifuss FE. Stupor following administration of valproic acid to patients receiving other antiepileptic drugs. Epilepsia 1979;20:697-703.
14. Zaret BS, Beckner RR, Marini AM, et al. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction. Neurology 1982;32:206-8.